Central Venous Access Ports in Children Treated for Hematopoietic Malignancies

Bucki, Bogusław; Tomaszewska, Renata; Karpe, Jacek; Stoksik, Piotr; Sońta-Jakimczyk, D; Szczepański, Tomasz

doi:10.1080/08880010802313632

Cited by 10 publications

(3 citation statements)

References 17 publications

(23 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although supportive care has improved, including antibiotic therapy during neutropenic fever, treatment‐related infections still cause significant morbidity and mortality . Treatment‐related mortality may occur in up to 3–5% of patients with leukaemia or lymphomas and is mainly caused by infections .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Early central line‐associated blood stream infections in children with cancer pose a risk for premature catheter removal

et al. 2018

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

“…To facilitate chemotherapy administration, as well as supportive care and blood sampling, the vast majority of children diagnosed with cancer are now provided with a central venous catheter (CVC; ). Despite their great benefits, CVCs can also be hazardous, as they are a common source of serious blood stream infections .…”

Section: Introductionmentioning

confidence: 99%

Early central line‐associated blood stream infections in children with cancer pose a risk for premature catheter removal

et al. 2018

View full text Add to dashboard Cite

show abstract

“…With intraluminal fibrin deposition, the risk of coagulase-negative staphylococci infection increases (van Rooden, Schippers, Guiot, et al, 2008). Over time, occlusion occurs in 3% to 36% of patients (Bucki et al, 2008;Dal Mollin, Guerretta, Mazzufero, & Rasero, 2009;Dillon et al, 2004;Kuhle et al, 2003;Ociepa, Maloney, Urasinski, & Sawicki, 2010) and has been shown to enhance the risk of infection (Jacobs, 2003).…”

Section: Review Of Literaturementioning

confidence: 99%

IV Catheter Care and Maintenance Minimizes Catheter-Related Blood Stream Infection

Macklin

2011

Cardiac Cath Lab Director

View full text Add to dashboard Cite

The elimination of catheter-related bloodstream infections (CR-BSI) requires meticulous intravenous (IV) catheter care. There are three different types of needlefree connectors and one intraluminal protection device that require different care regimens, including the correct usage of disinfectants, flushing techniques, and clamping sequences. The nurse must be able to identify which connector is in use and select the appropriate care. This care must be followed not only in the inpatient unit by the bedside nurse but also in areas that are providing diagnostic procedures such as the cardiac cath lab. Since bacterial adhesion to the intraluminal catheter wall is the primary building block of a CR-BSI, which may not present until days after initial inoculation, preventing intraluminal fluid pathway contamination is paramount with every access. In addition, many institutions have more than one type of connector available. This complicates the provision of consistent safe care. Split septum, negative mechanical valves, positive pressure mechanical valves, and intraluminal protection devices have specific care and maintenance requirements. This article discusses the different connector types, why each requires special care, how intraluminal fluid pathway contamination can lead to CR-BSI, and how simple nursing care and maintenance practices of connector septum swabbing and catheter flushing by the cardiac cath nurse can help prevent this serious complication.

show abstract

Catheter-related infections in pediatric patients with cancer

Cecinati

Brescia

Tagliaferri

et al. 2012

Eur J Clin Microbiol Infect Dis

View full text Add to dashboard Cite

Central venous catheters (CVCs) are essential in the management of pediatric patients receiving antineoplastic therapy or bone marrow transplants, and have significantly improved their quality of life, but CVC-related infectious complications are a major source of morbidity. It has been estimated that 14-51 % of the CVCs implanted in children with malignancies may be complicated by bacteremia, and that the incidence of infections is 1.4-1.9 episodes per 1,000 CVC days. However, there are few recent data concerning the epidemiology of CVC-related infections, the prevalence of antimicrobial resistance in their etiology, or the main factors associated with an increased risk of infection by type of catheter, patient age, the type of cancer, or the presence of neutropenia. Moreover, although various new strategies have been proposed in an attempt to reduce the risk of CVC-related infections, such as catheters impregnated with antiseptics/antibiotics, lock antibiotic prophylaxis, the use of ointments at the exit site, and antithrombotic prophylaxis, their real efficacy in children has not yet been demonstrated. The management of CVC-related infections remains difficult, mainly because of the number of still open questions (including the choice of optimal antimicrobial therapy because of the increasing isolation of multiresistant bacterial strains, treatment duration, whether catheters should be removed or not, the feasibility of guidewire exchange, and the usefulness of antibiotic lock therapy) and the lack of studies of children with cancer. Only well-designed, prospective clinical trials involving pediatric cancer patients can clarify optimal prevention and treatment strategies for CVC-related infections in this population.

show abstract

Central Venous Access Ports in Children Treated for Hematopoietic Malignancies

Cited by 10 publications

References 17 publications

Early central line‐associated blood stream infections in children with cancer pose a risk for premature catheter removal

Early central line‐associated blood stream infections in children with cancer pose a risk for premature catheter removal

IV Catheter Care and Maintenance Minimizes Catheter-Related Blood Stream Infection

Catheter-related infections in pediatric patients with cancer

Contact Info

Product

Resources

About